Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos Sells 4,647 Shares

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $5.30, for a total value of $24,629.10. Following the sale, the chief financial officer now owns 74,197 shares in the company, valued at approximately $393,244.10. This trade represents a 5.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Cibus Price Performance

Shares of CBUS opened at $4.78 on Friday. Cibus, Inc. has a 52-week low of $2.86 and a 52-week high of $23.18. The stock’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $8.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Old West Investment Management LLC boosted its holdings in shares of Cibus by 3.6% in the 2nd quarter. Old West Investment Management LLC now owns 53,247 shares of the company’s stock worth $524,000 after purchasing an additional 1,868 shares in the last quarter. FineMark National Bank & Trust boosted its stake in Cibus by 24.3% in the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after buying an additional 4,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Cibus by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after acquiring an additional 6,276 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Cibus during the third quarter worth approximately $33,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Cibus in the 2nd quarter worth approximately $214,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Cibus in a research report on Monday. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Cibus in a research note on Tuesday, October 22nd. Canaccord Genuity Group raised Cibus to a “strong-buy” rating in a research note on Friday, July 19th. Finally, Alliance Global Partners cut their price target on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a report on Tuesday, September 24th.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.